key: cord-1043251-hqyqme93 authors: Honavar, Santosh G title: The rise and rise of Indian Journal of Ophthalmology date: 2022-01-03 journal: Indian J Ophthalmol DOI: 10.4103/ijo.ijo_3110_21 sha: 6cd7925af172337a6873510cd63fa47a61cbefc8 doc_id: 1043251 cord_uid: hqyqme93 nan It is about four-and-a-half years since the current editorial board took over. Our dream was to make IJO bigger, brighter and better, to support and represent the soaring academic aspirations of Indian ophthalmologists and chronicle the beautifully unfolding growth story of Indian ophthalmology. We had resolved to work on the quality of the scientific content; timely, objective, and dispassionate review process; and transparency and punctuality in every aspect of the publication pipeline of the Journal. [2] I have reasons to believe that we have been able to achieve much of these. The growth in the number of manuscript submissions has been tremendous -almost 400% as compared to the 2016 baseline. What is very gratifying is the rise in submissions by Indian authors -from 575 in 2016 to 2785 in 2020 -a five-fold increase! The data clearly shows that IJO has been able to support the rising academic aspirations of Indian ophthalmologists. The overall impact of Indian ophthalmic research was globally ranked 6 (602 citable publications) in 2015. [3, 4] There has been a huge leap to rank 3 in 2020 with 1291 citable publications. [3, 4] Publications in IJO have helped add about 2000 unique authors to the pool of Indian researchers in the last six years. [4] Expanded publication opportunities that IJO currently provides will likely have a cascading positive effect on the rise in the academic impact of Indian ophthalmology. The IJO publication pipeline is well-oiled by now. The Journal is on-time, every time, with the eToC circulated in the third week of the previous month and the complete PDF/ flipbook in the mailbox by the first day of each month. The final manuscript acceptance time has been optimized -from 202 days for review, revision, and acceptance in 2016 to under 75 days in 2021. The average time for peer review and the initial decision has been reduced to less than 6 weeks as promised. We are currently working on reducing the average acceptance to publication time to 6 weeks. IJO has been able to support the readers through the current trying times by being the first among ophthalmology journals to publish several immediately relevant and practically important articles -be it the COVID-19 special issue with guidelines for ophthalmology and subspecialty practices, trends in education and training, intricacies of financial management, ophthalmic manifestations of COVID-19, and more recently, ophthalmic complications of COVID-19 vaccines. The multicentric collaborative effort on rhino-orbital-cerebral mucormycosis (ROCM), staging system and management guidelines have immensely helped streamline patient care across the world and tide over the storm of COVID-19 associated ROCM. [5, 6] The collaborative multicentric ROCM study (COSMIC Report 1) with 2826 patients from 102 treatment centers spanning 22 states in India [6] has received several citations and accolades; it was highlighted as a path-breaking publication in Oculoplastic Surgery/Orbit by the American Academy of Ophthalmology, American Ophthalmological Society and American Board of Ophthalmology in their 2021 symposium. We will endeavor to support you with current information and evidence-based guidelines to help you adapt to the new normal and practice safe ophthalmology until we see the pandemic through. The Journal could ably adapt to the financially challenging circumstances by going green -online access, flipbook and PDF for everyone, and paper copies to those who opted in. The next challenge was to process and publish the best of the deluge of 3823 manuscripts submitted in 2020 (about a 60% increase over 2415 manuscripts submitted in 2019). The Journal was able to rise to the challenge by incorporating new reviewers and initiating an expedited peer-review process for COVID-19 related manuscripts. Increasing the number of pages from 2113 in 2019 to 3084 in 2020 and rolling out a companion journal, IJO Case Reports in 2021 helped improve the publication timeline. On average, close to 60% of AIOS members access the monthly eToC within 72 hours after it is released. Online hits have touched an unprecedented high of 500,000 a month from across the world -one hit every 5 seconds! One of the objective assessments of a Journal's academic relevance is the Impact Factor, which has scaled up from 0.835 at the 2016 baseline to 1.848 in 2020 [ Fig. 1 ]. CiteScore has risen from 1.8 in 2016 to 2.8 in the last quarter of 2021 [ Fig. 1] , with the annual number of citations more than tripling from 1424 to 4719 in the same period [ Fig. 2 ]. IJO seems to be well-entrenched in the trajectory of growth. While concentrating on rising the impact of the Journal and initiating innovative manuscript formats to make it interesting and appealing to the entire spectrum of ophthalmologists, the priority is to support the soaring academic aspirations of Indian ophthalmologists and be an integral part of the robust growth of Indian ophthalmology. A collective effort and synergy between the authors, Journal, and readers -authors submitting the best of their works to IJO by choice, the Journal continuing to optimize the peer review and publication timelines, and the discerning readers accessing the publications to update their knowledge and adapt contemporary practice patterns, is bound to take us to a new high. "Hope smiles from the threshold of the year to come, whispering, 'It will be happier.'" -Lord Tennyson Indian Journal of Ophthalmology-The journey so far Indian Journal of Ophthalmology-On the right path Ophthalmic research in India-Revolution in evolution Code mucor: Guidelines for the diagnosis, staging, and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19 Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India-Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) The rise and rise of Indian Journal of Ophthalmology Figure 1: Impact Factor and CiteScore of IJO over the years (2011 to 2021) show a rising trend This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.